Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Lowered to Hold at Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

ZLDPF has been the subject of several other research reports. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Finally, Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

Shares of Zealand Pharma A/S stock opened at $36.75 on Tuesday. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a 52 week low of $33.08 and a 52 week high of $83.12. The firm’s 50 day moving average is $38.85 and its two-hundred day moving average is $46.81. The firm has a market capitalization of $2.63 billion, a P/E ratio of 6.09 and a beta of 0.99.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.